Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Zynerba Announces Negative Top-Line Results

Aug 7, 2017 • 11:10 AM EDT
5 stories (1).png
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

GW Pharmaceuticals (GWPH) is an industry leader for a reason…

Developing cannabis-based pharmaceutical treatments is not as easy as it looks and Zynerba Pharmaceuticals (ZYNE) is learning that the hard way.

Zynerba is trading considerably lower after reporting negative top-line results from its double-blind placebo controlled Phase 2 clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with focal seizures.

Zynerba’s Top-Line Data Misses The Mark

Zynerba announced that its Phase 2 clinical trial did not demonstrate statistically significant results during the treatment period.

When compared to the baseline, patients on the low dose of ZYN002 recorded an 18.4% median reduction in focal seizures, while patients on the high dose recorded an 14.0% median reduction and patients on placebo recorded an 8.7% median reduction.

Zynerba Chairman and CEO Armando Anido said, “We are very disappointed that the STAR 1 trial did not meet its primary endpoint in this patient population. We are continuing to evaluate this study and the ongoing STAR 2 open label study to determine next steps with ZYN002 in adult epilepsy patients with focal seizures. I’d like to thank the patients, coordinators and investigators, as well as the development team at Zynerba, for their time and energies in conducting this very important trial.”

Although the top-line data was less-than-impressive, CEO Anido believes that the results show that ZYN002 has a favorable safety and tolerability profile, which is encouraging as the firm looks to develop ZYN002 as a treatment for a wide range of indications.

A Story to Watch as Catalysts Lie Ahead

While these results will mostly likely be a headwind for Zynerba in the near-term, the company will present top-line data from its ZYN002 Clinical trial in Osteoarthritis later this month, followed by top-line data from its FAB-C study in Fragile X syndrome before October.

We plan to monitor how the market responds to these results and expect to see the shares give up its gains from Friday. With several data readouts expected in the coming months, we believe Zynerba is a stock to watch.

Keep your eye on this story as we expect Zynerba to trade volatile today! 

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.